[Skip to Content]
[Skip to Content Landing]
Other Articles
June 2, 1951

A NEW NITROGEN MUSTARD CONGENER IN CANCER CHEMOTHERAPY

JAMA. 1951;146(5):480. doi:10.1001/jama.1951.03670050062017
Abstract

During the past nine years the nitrogen mustard methyl-bis(beta-chloroethyl)amine (HN2) has found a definite place in the treatment of malignant lymphomas, certain blood dyscrasias and inoperable bronchogenic carcinoma. Efforts have been made to discover a congener of nitrogen mustard that would be more effective against malignant cells and less toxic to normal cells. Recently, a new compound has been studied in the laboratory1 and the clinic2 which has certain advantages over nitrogen mustard HN2 and which offers the possibility of extending the usefulness of this type of chemotherapy.

The new compound has already acquired several synonyms: triethylene melamine, TEM, and 2,4,6-triethyleneimino-s-triazine. It was first synthesized in Germany and used there in a commercial process for improving the finish of rayon fabrics. The chemical relationship of triethylene melamine to methyl-bis(beta-chlorethyl)amine led to the cancer chemotherapeutic investigations of the compound in England and America.

The experimental

First Page Preview View Large
First page PDF preview
First page PDF preview
×